therapiAI was founded in 2018 by experts in biotechnology, artificial intelligence, pharmaceutical engineering, quality systems, and intellectual property.
Through extensive field research and on-site interviews, we observed a consistent pattern across manufacturing facilities: although pharmaceutical companies generate vast amounts of data, they struggle with fragmented systems, inconsistent formats, complex workflows, and limited modularization. Combined with long experimental cycles and strict regulatory requirements, most AI tools on the market fail to create real value in GMP environments.

We chose a more difficult path—focusing on the most demanding and complex segment of the industry: pharmaceutical CDMOs.
This decision came not from market size, but from a clear mission: to build AI Agents that truly understand biomanufacturing environments, deploy quickly, and earn trust, defining a new standard for intelligent pharmaceutical operations.

To achieve this, we developed a multi-model AI engine combined with a generative-AI platform that allows CDMOs to assemble and deploy their own AI Agents like modular components.
Our AI is not just an analytical tool—it interacts with real-time data, participates in decision-making, and works alongside domain experts as an intelligent partner.

We believe trust is earned through outcomes. Lasting value is only created when AI genuinely solves problems on the production floor.

Today, therapiAI has partnered with more than 30 pharmaceutical CDMOs and continues to expand globally—building on our R&D base in Taiwan, establishing operations in Japan, and collaborating deeply with leading CDMO organizations.
Our ambition goes beyond serving individual clients. We aim to build the world’s AI Agent platform for pharmaceutical manufacturing.
This is not a race of technology, but a long-term effort centered on trust, expertise, and the future standards of the industry.